[1]Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology, 2005, 41: 1179-1197.
[2]Ostapowicz G, Fontana RJ, Schiodt FV,et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med, 2002, 137: 947-954.
[3]O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet, 1993, 342: 273-275.
[4]Tandon BN, Bernauau J, O扜rady J, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol, 1999, 14: 403-404.
[5]Diehl AM. Acute and chronic liver failure and hepatic encephalopaphy. In: Goldman L, Bennett JC, eds. Cecil textbook of medicine. Philadelphia: Saunders, 2000. 813-816.
[6]Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver, 2002, 22 (Suppl 2): 5-13.
[7]Wang YM, Chen YK, Gu CH, et al. Reevaluation of the nomenclature and diagnostic criteria in 477 patients with severe hepatitis. Zhonghua Ganzangbing Zazhi, 2000, 8: 261-263.
[8]Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for viral hepatitis. Zhonghua Ganzangbing Zazhi, 2000, 8: 324-329.
[9]Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology, 2002, 35: 716-721.
[10]Sun YL, Zhao JM, Zhou GD, et al. Cut-off period of subclassification and pathological features of severe hepatitis based on clinical and pathological **yses. Zhonghua Shiyan He Linchuang Bingduxue Zazhi, 2003, 17:270-273.
[13]Li MD, Nie QH. Clinical and experimental studies on glucocorticosteroid therapy for severe hepatitis. Shiyong Ganzangbing Zazhi, 2005, 8: 1-6.
李梦东,聂青和.糖皮质激素治疗重型肝炎的临床及实验研究.实用肝脏病杂志,2005,8:1-6.
[14]Chen CX, Guo SM, Liu B, et al. Glycocorticosteroid administration prevents fulminant hepatic failure occurrence in patients with chronic hepatitis B of severe degree. Zhonghua Ganzangbing Zazhi, 2003, 11: 37-40.
[15]Li LJ, Yang Q, Huang JR, et al. Effect of artificial liver support system on patients with severe viral hepatitis: a study of four hundred cases. World J Gastroenterol, 2004, 10: 2984-2988.
[16]Li LJ, Du WB, Zhang YM, et al. Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs. J Hepatol, 2006, 44: 317-324.
[17]Guideline of indicatio, criterion and technology for the application of artificial liver. Zhonghua Chuanranbing Zazhi, 2002, 20: 254-258.
人工肝支持系统治疗指征、标准及技术指南.中华传染病杂志,2002,20:254-258.
[18]Zheng SS, Xu X. To develop liver transplantation in Chin. Zhonghua Gandan Waike Zazhi, 2005, 11:437-439.